Oramed Pharmaceuticals Inc. (ORMP) stock
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.71−0.32 (-7.94%)
Close on Nov 13, 2026Market cap $154.33MP/E 1.1Yield 6.74%
Oramed Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Oramed Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $3.58M, down 38.8% year over year. For fiscal 2025 it was $6.38M, up 0.9% from the year before. Over ten years it grew 6.9% a year on average. The highest annual figure on record is $20.99M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.38M | +0.9% |
| FY2024 | Dec 31, 2024 | $6.32M | -29.5% |
| FY2023 | Dec 31, 2023 | $8.97M | -57.3% |
| FY2021 | Aug 31, 2021 | $20.99M | +105.1% |
| FY2020 | Aug 31, 2020 | $10.24M | -24.3% |
| FY2019 | Aug 31, 2019 | $13.52M | +12.9% |
| FY2018 | Aug 31, 2018 | $11.98M | +16.5% |
| FY2017 | Aug 31, 2017 | $10.28M | +33.4% |
| FY2016 | Aug 31, 2016 | $7.71M | +61.2% |
| FY2015 | Aug 31, 2015 | $4.78M | +45.9% |
| FY2014 | Aug 31, 2014 | $3.28M | – |
| FY2013 | Aug 31, 2013 | -$2.27M | -235.2% |
| FY2012 | Aug 31, 2012 | $1.68M | +45.0% |
| FY2011 | Aug 31, 2011 | $1.16M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $0 | -100.0% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $1.59M | -27.7% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $1.99M | +36.1% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $1.15M | -48.6% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $1.03M | -28.3% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $2.21M | +87.1% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $1.46M | -17.3% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $2.24M | +134.3% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $1.44M | -20.8% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $1.18M | -73.4% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $1.77M | -69.8% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $957.00K | -82.6% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $1.82M | -52.9% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $4.43M | -23.3% |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | $5.84M | +96.9% |
| Q3 FY2021CQ2 2021 | May 31, 2021 | $5.50M | +185.8% |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | $3.87M | +16.5% |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | $5.77M | +185.6% |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | $2.97M | +34.9% |
| Q3 FY2020CQ2 2020 | May 31, 2020 | $1.93M | -50.1% |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | $3.32M | +21.4% |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | $2.02M | -51.8% |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | $2.20M | -19.2% |
| Q3 FY2019CQ2 2019 | May 31, 2019 | $3.86M | +65.9% |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | $2.73M | +7.8% |
| Q3 FY2018CQ2 2018 | May 31, 2018 | $4.19M | +85.0% |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | $2.72M | -12.8% |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | $2.33M | -1.1% |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | $2.54M | -79.9% |
| Q3 FY2017CQ2 2017 | May 31, 2017 | $2.27M | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | $3.13M | +139.8% |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | $2.35M | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | $12.62M | +784.0% |
| Q3 FY2016CQ2 2016 | May 31, 2016 | -$1.71M | -286.9% |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | $1.30M | – |
| Q1 FY2016CQ4 2015 | Nov 30, 2015 | -$1.90M | – |
| Q4 FY2015CQ3 2015 | Aug 31, 2015 | $1.43M | – |
| Q3 FY2015CQ2 2015 | May 31, 2015 | $915.00K | – |
See a number that looks wrong?